121 patents
Page 3 of 7
Utility
Methods of Preparing Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulators
21 Jul 22
The present invention provides methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators, and compositions having low impurity levels.
Jeffrey Mark DENER, Hazel Joan HUNT, Travis LEMONS, Gary REID, Kilian GARREC, Thomas C. STEPHENS, Adam Daisuke GAMMACK YAMAGATA, Yunguo LU
Filed: 22 Dec 21
Utility
Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
19 Jul 22
Andrew Greenstein, Stacie Shepherd, Andreas G. Moraitis
Filed: 18 Dec 19
Utility
Method of Preparing Pyrimidine Cyclohexyl Glucocorticoid Receptor Modulators
14 Jul 22
The present invention provides methods of preparing 2-amino-6-((1r,4r)-4-phenylcyclohexyl)-5-(3-(trifluoromethyl)benzyl)pyrimidin-4(3H)-one, and 2-amino-6-((1r,4r)-4-phenylcyclohexyl)-5-(3-(trifluoromethyl)benzyl)pyrimidin-4(3H)-one monohydrate, as well as new intermediate compounds.
Jeffrey Mark Dener, Hazel Joan Hunt, Nicholas David Tyrrell
Filed: 20 Dec 21
Utility
Concomitant Administration of Glucocorticoid Receptor Modulator Relacorilant and Paclitaxel, a Dual Substrate of CYP2C8 and CYP3A4
16 Jun 22
Hazel Hunt, Joseph Custodio
Filed: 15 Feb 22
Utility
Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome
10 May 22
Improved methods and systems for diagnosing and for treating Cushing's syndrome and Cushing's Disease are provided herein, including methods and systems for concurrently treating Cushing's syndrome and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome in a patient with an established diagnosis of ACTH-dependent Cushing's syndrome.
Andreas G. Moraitis
Filed: 12 Oct 18
Utility
Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
29 Mar 22
Hazel Hunt, Joseph Custodio
Filed: 26 May 21
Utility
Concomitant Administration of Glucocorticoid Receptor Modulators and CYP3A Inhibitors
24 Mar 22
Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor modulator (GRM) and steroidogenesis inhibitors, and by concomitant administration of a GRM and CYP3A inhibitors.
Joseph K. Belanoff
Filed: 7 Dec 21
Utility
Methods of Treating Neuroepithelial Tumors Using Selective Glucocorticoid Receptor Modulators
17 Mar 22
Applicant discloses methods for treating a glucocorticoid receptor positive (GR+) neuroepithelial tumor in a subject, comprising administering a selective glucocorticoid receptor modulator (SGRM) in an amount effective to reduce the tumor load in subject.
Andreas G. Moraitis
Filed: 19 Nov 21
Utility
Methods for treating Cushing's syndrome
8 Mar 22
Methods are provided for assessing a clinical response to a glucocorticoid receptor antagonist (GRA) in a human subject and for diagnosing Cushing's syndrome.
Joseph K. Belanoff, Hazel Hunt, John Francis Unitt, Andreas G. Moraitis
Filed: 12 Dec 17
Utility
Use of Glucocorticoid Receptor Antagonists In Combination with Glucocorticoids to Treat Adrenal Insufficiency
3 Mar 22
This invention provides for a method of treating secondary adrenal insufficiency by co-administrating therapeutically effective amounts of a glucocorticoid and a glucocorticoid receptor antagonist to the patient in need thereof.
Andreas G. MORAITIS, Pejman COHAN, Joseph K. BELANOFF
Filed: 12 Nov 21
Utility
Methods for Imaging and Treatment of Somatostatin-Receptor Positive Tumors
3 Mar 22
Methods for treating, identifying and localizing tumors expressing somatostatin receptors (SRs), including methods of enhancing the efficacy of imaging techniques by administration of a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (HKGRM) effective to increase SR expression in tumors.
Andreas G. Moraitis
Filed: 19 Dec 19
Utility
Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
1 Feb 22
Andrew Greenstein, Stacie Shepherd, Andreas G. Moraitis
Filed: 17 Jan 20
Utility
Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
4 Jan 22
Applicant discloses methods for treating a glucocorticoid receptor positive (GR+) neuroepithelial tumor in a subject, comprising administering a selective glucocorticoid receptor modulator (SGRM) in an amount effective to reduce the tumor load in a subject.
Andreas G. Moraitis
Filed: 18 Jun 18
Utility
Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
21 Dec 21
This invention provides for a method of treating secondary adrenal insufficiency by co-administrating therapeutically effective amounts of a glucocorticoid and a glucocorticoid receptor antagonist to the patient in need thereof.
Andreas G. Moraitis, Pejman Cohan, Joseph K. Belanoff
Filed: 11 Mar 20
Utility
Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
21 Dec 21
This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia.
Andreas Moraitis
Filed: 30 Apr 19
Utility
Concomitant Administration of Glucocorticoid Receptor Modulator Relacorilant and CYP2C9 Substrates
2 Dec 21
Hazel Hunt, Joseph Custodio
Filed: 26 May 21
Utility
Concomitant Administration of Glucocorticoid Receptor Modulator Relacorilant and CYP2C8 Substrates
2 Dec 21
Hazel Hunt, Joseph Custodio
Filed: 26 May 21
Utility
Concomitant Administration of Glucocorticoid Receptor Modulator Relacorilant and Paclitaxel, a Dual Substrate of CYP2C8 and CYP3A4
2 Dec 21
Hazel Hunt, Joseph Custodio
Filed: 26 May 21
Utility
Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulators
2 Dec 21
The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators, including their use for treating amyotrophic lateral sclerosis (ALS).
Hazel Hunt, Tony Johnson, Nicholas Ray, Iain Walters
Filed: 28 Jul 21
Utility
Formulations of Pyrimidine Cyclohexyl Glucocorticoid Receptor Modulators
25 Nov 21
The present invention provides formulations of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, and methods of making and using the same.
Yip-Fong CHIA, Stephen ARBOLEDA, Yan ALSMEYER, Gordon DAVIS, Tyler CLIKEMAN
Filed: 5 May 21